November 3, 2026 · Radiology · DOI: 10.1148/radiol.260517

Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma.

Listen to this summary

This phase 2 trial asked whether CD38-targeted 89Zr-DFO-daratumumab immuno-PET/CT could detect multiple myeloma better than standard 18F-FDG PET/CT in 60 participants. Overall detection rates were similar (43% for the immuno-PET versus 47% for FDG PET/CT, P = .81), but the immuno-PET alone identified active myeloma in 13% (8 of 60) of participants, which was confirmed on biopsy in those cases. The findings suggest that CD38-targeted immuno-PET can reveal disease missed by FDG PET/CT in some patients.

Gary A Ulaner, Russ A Kuker, Benjamin Diamond, James Hoffman, Pooja Motwani, Ben Goldenson, Yaser Homsi, Gary Schiller, Beth Thomsen, Alanna Vossen, Dickran Kazandjian, C Ola Landgren

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play